Children's Hospital is part of the UPMC family.
The PAZNTIS multicenter trial by the Children’s Oncology Group studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work in treating young patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). In adults with certain NRSTS, pazopanib has been shown to have anti-tumor effects.
Subject to certain exclusion criteria, this study is open to pediatric patients of both genders, age 2 or greater, who have been newly diagnosed with an intermediate- or high-risk NRSTS that could not be removed by surgery at the time of diagnosis.
Males and Females: Ages 2 years and up
For this study, participants will receive oral doses of pazopanib along with standard chemotherapy for the 12-week induction phase. If the tumor has responded to therapy, it will be removed by surgery and the patient will advance to the 9-week continuation phase, during which the study drug will continue to be provided with chemotherapy, possibly supported by radiation therapy and additional surgery.
Visits: Same number as required for standard chemotherapy
Duration: About 6 months
Children’s Oncology Group (ARST1321)
National Cancer Institute
Study Description at National Institutes of Health
Jean Tersak, MD
For more information about the study or enrollment, please contact:
Jean Tersak, MD
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to make a donation online.